AMLX | Amylyx Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.56 - 3.84
52 Week Range	1.5750 - 7.27
Beta	1.19
Implied Volatility	307.72%
IV Rank	37.36%
Day's Volume	515,388
Average Volume	824,578
Shares Outstanding	88,602,470
Market Cap	324,285,040
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-01-07

Valuation
Profitability
Growth
Health
P/E Ratio	-0.83
Forward P/E Ratio	N/A
EPS	-4.43
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	384
Country	USA
Website	AMLX

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

AMLX's peers: ABOS, ACLX, ALNY, TERN, INZY, XFOR, DAWN, MREO, PDSB, HOOK, ANNX, APLS, ARCT, ARGX, ARQT, ARWR, ASND, AUTL, AXSM, BBIO, BHVN, BIVI, BMRN, BPMC, BTAI, CNTX, CYTK, ELDN, GLSI, GLTO, GMAB, GOSS, GNLX, IDYA, IMVT, INVA, ITOS, LEGN, LQDA, MIRM, MRSN, OCUL, PHAT, PRTG, QURE, RARE, RLAY, RPRX, SAGE, SANA, SWTX, VIR, VRNA, WVE, MLTX, IRON, GPCR

*Chart delayed

Analyzing fundamentals for AMLX we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see AMLX Fundamentals page.

Watching at AMLX technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on AMLX Technicals page.